What Happened?
Gaithersburg, -based Novavax Retired John Herrmann as Executive Vice President and Chief Legal Officer
About the Company
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
About the Person
John Herrmann is Executive Vice President and Chief Legal Officer at Novavax. Previously, John held various senior legal leadership roles in the industry.
Info Source
News
Short Profile